C-KZ8KEVerZom
exosomes, extracellular vesicles, regenerative medicine
repairingextracellular vesicle
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
←All companiesC-KZ8K
C-KZ8KC-KZ8Kexosomes, extracellular vesicles, regenerative medicine
0-100 chain-logic scale · 15 dimensions · scored on public evidence
EVerZom exosomes, extracellular vesicles, regenerative medicine
EVerZom is an exosome-based biotech company founded in 2019. Its platform covers cell sourcing, exosome generation, exosome loading, and formulation. The company is developing proprietary regenerative medicine products for digestive tissue healing and liver and kidney regeneration, while also pursuing co-development partnerships.
The published score reflects a curated read of public evidence across 16 dimensions. Each dimension below shows the rationale we used. Disagree with a reading? Tell us where we are wrong →
Higher up = higher Eternal Search score. Further right = closer to achieving real longevity outcomes (early mechanism → translational → near-term readout). Bubble size = capital deployed. Watch for MISMATCHES: big bubbles on the left are well-capitalized but far from goals; small bubbles on the right are doing more with less.
EVerZom — Early mechanism · Lower middle. Derived deterministically from 7 extracted project(s). Most-advanced status: preclinical. Band: early_mechanism. Aging-relevance not LLM-reviewed in this pass.
Source: Deterministic